To receive comprehensive knowledge on product characteristics (structure, function and biological activities)
|
|
|
|
|
|
To receive clinical evidence/data from pivotal phase II/III trial (efficacy, safety), which is published in peer-reviewed journal
|
|
|
|
|
|
To realize that the company understands the target patients’ needs and provides with data from patients reported outcomes
|
|
|
|
|
|
To receive evidence/data from Health Economic Outcome Research about product effectiveness (direct or indirect comparison) versus available treatment options (if any)
|
|
|
|
|
|
Access or availability of early access provision for that product (prior to marketing authorization) and registries (pre- and post-approval to monitor the patients)
|
|
|
|
|
|
That the pharmaceutical company is demonstrating scientific engagements with respective medical societies to improve research and education in that respective therapeutic area
|
|
|
|
|
|
That knowledge from Advisory Boards with experts in the fields has been collected and implemented into product strategy and product lifecycle
|
|
|
|
|
|
That the pharmaceutical company demonstrates their commitment to patients and caregivers, with additional services (not related to product)
|
|
|
|
|
|
That multiple communication channels are used to reach out directly to end-consumers/patients (TV, press-newspapers, e-commerce, twitter, facebook, other on-line/social media, etc) to inform about that product and educate about disease.
|
|
|
|
|
|
The opportunity to receive information about product at company promotional symposia and/or commercial booth at congresses
|
|
|
|
|
|
To receive education about the disease and therapeutic area, supported by company via grant or travel to congress
|
|
|
|
|
|
That the pharmaceutical company is engaged in co-operation with patient and care giver groups
|
|
|
|
|
|
Face-to-face meetings, hospital visits of sales representatives from the pharmaceutical company
|
|
|
|
|
|
Face-to-face meetings, hospital visits of Medical-Science-Liaison- representatives from the pharmaceutical company
|
|
|
|
|
|